Journal of Community Health

, Volume 34, Issue 2, pp 135–143 | Cite as

The Nurse’s Role in the Prevention of Cervical Cancer Among Underserved and Minority Populations

Original Paper

Abstract

Since the implementation of the Papanicolaou test, there has been a significant decline in the incidence of cervical cancer over the last 50 years. Despite this reduction, each year there are approximately 11,000 women in the United States diagnosed with cervical cancer, the second most common type of cancer in women worldwide. Infection with oncogenic human papillomavirus (HPV) is necessary for the development of precancerous lesions and the progression to cervical cancer. For those diagnosed with an HPV infection or cervical cancer, a considerable personal and financial burden often results. Recent analyses estimate that the total direct costs associated with cervical dysplasia and cancer are extensive. Additionally, a patient’s quality of life (social, emotional, and sexual functioning) is adversely affected following a diagnosis with an HPV infection or cervical cancer. The data also show disparities in the incidence of cervical cancer and barriers that may contribute to these phenomena in underserved populations. National programs have been implemented and can help reduce the burden of disease, but vaccination against HPV remains the primary method of prevention. In the healthcare field, nurses play many roles, a prominent one being a patient educator. As a result, there is a need to educate nurses about the risks and impact of HPV and cervical cancer. Nurses can be instrumental in educating the public about vaccination and increasing awareness of HPV and cervical cancer among the underserved.

Keywords

Cervical cancer Human papillomavirus Screening Vaccination Nurses 

Notes

Acknowledgements

Editorial support was sponsored by GlaxoSmithKline, and provided by Tara N. Miller, PhD, at AlphaBioCom.

References

  1. 1.
    Ries, L., Harkins, D., Krapcho, M., Mariotto, A., Miller, B. A., Feuer, E. J., et al. (Eds.), SEER Cancer Statistics Review, 1975–2004. Bethesda: National Cancer Institute, based on November 2005 SEER data submission, posted to the SEER web site. Available at http://seer.cancer.gov/csr/1975_2004/. Accessed 3 February 2008.
  2. 2.
    ACS. American Cancer Society: Cancer Facts & Figures. (2008). Available at http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf. Accessed 1 April 2008.
  3. 3.
    Walboomers, J. M., Jacobs, M. V., Manos, M. M., et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology, 189(1), 12–19.PubMedCrossRefGoogle Scholar
  4. 4.
    Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J., & Shah, K. V. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 55(4), 244–265.PubMedGoogle Scholar
  5. 5.
    Dunne, E. F., Unger, E. R., Sternberg, M., et al. (2007). Prevalence of HPV infection among females in the United States. Jama, 297(8), 813–819.PubMedCrossRefGoogle Scholar
  6. 6.
    CDC. (2007). The pink book: Epidemiology and prevention of vaccine preventable diseases. Updated 10th ed.Google Scholar
  7. 7.
    Viscidi, R. P., Schiffman, M., Hildesheim, A., et al. (2004). Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica. Cancer Epidemiology, Biomarkers and Prevention, 13(2), 324–327.PubMedCrossRefGoogle Scholar
  8. 8.
    U.S. Census Bureau. (2004). U.S. interim projections by age, sex, race, and hispanic origin. Available at http://www.census.gov/ipc/www/usinterimproj/. Accessed 5 March 2008.
  9. 9.
    Saslow, D., Castle, P. E., Cox, J. T., et al. (2007). American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA: A Cancer Journal for Clinicians, 57(1), 7–28.CrossRefGoogle Scholar
  10. 10.
    Benard, V. B., Lawson, H. W., Eheman, C. R., Anderson, C., & Helsel, W. (2005). Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstetrics and Gynecology, 105(6), 1323–1328.PubMedGoogle Scholar
  11. 11.
    Smith, J. S., Lindsay, L., Hoots, B., et al. (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. International Journal of Cancer, 121, 621–632.CrossRefGoogle Scholar
  12. 12.
    de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U., & zur Hausen, H. (2004). Classification of papillomaviruses. Virology, 324, 17–27.PubMedCrossRefGoogle Scholar
  13. 13.
    Castellsague, X., Diaz, M., de Sanjose, S., et al. (2006). Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. Journal of the National Cancer Institute, 98(5), 303–315.PubMedCrossRefGoogle Scholar
  14. 14.
    Vizcaino, A. P., Moreno, V., Bosch, F. X., et al. (2000). International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. International Journal of Cancer, 86(3), 429–435.CrossRefGoogle Scholar
  15. 15.
    Vizcaino, A. P., Moreno, V., Bosch, F. X., Munoz, N., Barros-Dios, X. M., & Parkin, D. M. (1998). International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. International Journal of Cancer, 75(4), 536–545.CrossRefGoogle Scholar
  16. 16.
    Bulk, S., Visser, O., Rozendaal, L., Verheijen, R. H., & Meijer, C. J. (2005). Cervical cancer in the Netherlands 1989–1998: Decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. International Journal of Cancer, 113(6), 1005–1009.CrossRefGoogle Scholar
  17. 17.
    Krane, J. F., Granter, S. R., Trask, C. E., Hogan, C. L., & Lee, K. R. (2001). Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: A study of 49 cases. Cancer, 93(1), 8–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Mitchell, H., Medley, G., Gordon, I., & Giles, G. (1995). Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: No strong evidence of benefit. British Journal of Cancer, 71(4), 894–897.PubMedGoogle Scholar
  19. 19.
    Raab, S. S. (2000). Can glandular lesions be diagnosed in pap smear cytology? Diagnostic Cytopathology, 23(2), 127–133.PubMedCrossRefGoogle Scholar
  20. 20.
    Einstein, M., & Burk, R. (2001). Persistent human papillomavirus infection: Definitions and clinical implications. Papillomavirus Report, 12, 119.Google Scholar
  21. 21.
    Kjaer, S. K., van den Brule, A. J., Paull, G., et al. (2002). Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. Bmj, 325(7364), 572.PubMedCrossRefGoogle Scholar
  22. 22.
    Benedet, J. L., Bender, H., Jones, H, 3rd, Ngan, H. Y., & Pecorelli, S. (2000). FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynaecology and Obstetrics, 70(2), 209–262.PubMedCrossRefGoogle Scholar
  23. 23.
    Wright, T. C., Jr. (2006). HPV DNA testing for cervical cancer screening. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. International Journal of Gynaecology and Obstetrics, 95(Suppl 1), S239–S246.Google Scholar
  24. 24.
    Wright, T. C., Van Damme, P., Schmitt, H. J., & Meheus, A. (2006). Chapter 14: HPV vaccine introduction in industrialized countries. Vaccine, 24(Suppl 3), S122–S131.CrossRefGoogle Scholar
  25. 25.
    Stanley, M. (2006). Immune responses to human papillomavirus. Vaccine, 24(Suppl 1), S16–S22.PubMedCrossRefGoogle Scholar
  26. 26.
    Le Bon, A., & Tough, D. F. (2002). Links between innate and adaptive immunity via type I interferon. Current Opinion in Immunology, 14(4), 432–436.PubMedCrossRefGoogle Scholar
  27. 27.
    Theofilopoulos, A. N., Baccala, R., Beutler, B., & Kono, D. H. (2005). Type I interferons (alpha/beta) in immunity and autoimmunity. Annual Review of Immunology, 23, 307–336.PubMedCrossRefGoogle Scholar
  28. 28.
    Nardelli-Haefliger, D., Wirthner, D., Schiller, J. T., et al. (2003). Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. Journal of the National Cancer Institute, 95(15), 1128–1137.PubMedGoogle Scholar
  29. 29.
    Day, P. M., Gambhira, R., Roden, R., Lowy, D. R., & Schiller, J. T. (2008). Mechanisms of HPV16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. Journal of Virology, 82(9), 4638–4646.PubMedCrossRefGoogle Scholar
  30. 30.
    Einstein, M. H. (2008). Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunology, Immunotherapy, 57(4), 443–451.PubMedCrossRefGoogle Scholar
  31. 31.
    Hildesheim, A., Herrero, R., Wacholder, S., et al. (2007). Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. Jama, 298(7), 743–753.PubMedCrossRefGoogle Scholar
  32. 32.
    Chesson, H. W., Ekwueme, D. U., Saraiya, M., & Markowitz, L. E. (2008). Cost-effectiveness of human papillomavirus vaccination in the United States. Emerging Infectious Diseases, 14(2), 244–251.PubMedCrossRefGoogle Scholar
  33. 33.
    Insinga, R. P. (2006). Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues, 16(5), 236–242.PubMedCrossRefGoogle Scholar
  34. 34.
    Fleurence, R. L., Dixon, J. M., Milanova, T. F., & Beusterien, K. M. (2007). Review of the economic and quality-of-life burden of cervical human papillomavirus disease. American Journal of Obstetrics and Gynecology, 196(3), 206–212.PubMedCrossRefGoogle Scholar
  35. 35.
    Pearman, T. (2003). Quality of life and psychosocial adjustment in gynecologic cancer survivors. Health and Quality of Life Outcomes, 1(1), 33.PubMedCrossRefGoogle Scholar
  36. 36.
    Basen-Engquist, K., Paskett, E. D., Buzaglo, J., et al. (2003). Cervical cancer. Cancer, 98(9 Suppl), 2009–2014.PubMedCrossRefGoogle Scholar
  37. 37.
    Idestrom, M., Milsom, I., & Andersson-Ellstrom, A. (2003). Women’s experience of coping with a positive Pap smear: A register-based study of women with two consecutive Pap smears reported as CIN 1. Acta Obstetricia et Gynecologica Scandinavica, 82(8), 756–761.PubMedCrossRefGoogle Scholar
  38. 38.
    Lerman, C., Miller, S. M., Scarborough, R., Hanjani, P., Nolte, S., & Smith, D. (1991). Adverse psychologic consequences of positive cytologic cervical screening. American Journal of Obstetrics and Gynecology, 165(3), 658–662.PubMedGoogle Scholar
  39. 39.
    Clarke, P., Ebel, C., Catotti, D. N., & Stewart, S. (1996). The psychosocial impact of human papillomavirus infection: Implications for health care providers. International Journal of STD and AIDS, 7(3), 197–200.PubMedCrossRefGoogle Scholar
  40. 40.
    Filiberti, A., Tamburini, M., Stefanon, B., et al. (1993). Psychological aspects of genital human papillomavirus infection: A preliminary report. Journal of Psychosomatic Obstetrics and Gynaecology, 14(2), 145–152.PubMedCrossRefGoogle Scholar
  41. 41.
    Maissi, E., Marteau, T. M., Hankins, M., Moss, S., Legood, R., & Gray, A. (2004). Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: Cross sectional questionnaire study. Bmj, 328(7451), 1293.PubMedCrossRefGoogle Scholar
  42. 42.
    McCaffery, K., Waller, J., Forrest, S., Cadman, L., Szarewski, A., & Wardle, J. (2004). Testing positive for human papillomavirus in routine cervical screening: Examination of psychosocial impact. Bjog, 111(12), 1437–1443.PubMedGoogle Scholar
  43. 43.
    Reed, B. D., Ruffin, M. T., Gorenflo, D. W., & Zazove, P. (1999). The psychosexual impact of human papillomavirus cervical infections. Journal of Family Practice, 48(2), 110–116.PubMedGoogle Scholar
  44. 44.
    Andersen, B. L. (1996). Stress and quality of life following cervical cancer. Journal of the National Cancer Institute. Monographs, 21, 65–70.PubMedGoogle Scholar
  45. 45.
    DATA 2010. The Healthy People 2010 database. The Centers for Disease Control and Prevention. Available at http://wonder.cdc.gov/data2010/. Accessed 7 January 2008.
  46. 46.
    Coronado, G. D., Thompson, B., Koepsell, T. D., Schwartz, S. M., & McLerran, D. (2004). Use of Pap test among Hispanics and non-Hispanic whites in a rural setting. Preventive Medicine, 38(6), 713–722.PubMedCrossRefGoogle Scholar
  47. 47.
    del Carmen, M. G., Findley, M., Muzikansky, A., et al. (2007). Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecologic Oncology, 104(1), 70–76.PubMedCrossRefGoogle Scholar
  48. 48.
    De Alba, I., & Sweningson, J. M. (2006). English proficiency and physicians’ recommendation of Pap smears among Hispanics. Cancer Detection and Prevention, 30(3), 292–296.PubMedCrossRefGoogle Scholar
  49. 49.
    Behbakht, K., Lynch, A., Teal, S., Degeest, K., & Massad, S. (2004). Social and cultural barriers to Papanicolaou test screening in an urban population. Obstetrics and Gynecology, 104(6), 1355–1361.PubMedGoogle Scholar
  50. 50.
    Eisenberg, J. M. (1979). Sociologic influences on decision-making by clinicians. Annals of Internal Medicine, 90(6), 957–964.PubMedGoogle Scholar
  51. 51.
    Nguyen, T. T., McPhee, S. J., Nguyen, T., Lam, T., & Mock, J. (2002). Predictors of cervical Pap smear screening awareness, intention, and receipt among Vietnamese-American women. American Journal of Preventive Medicine, 23(3), 207–214.PubMedCrossRefGoogle Scholar
  52. 52.
    Newmann, S. J., & Garner, E. O. (2005). Social inequities along the cervical cancer continuum: A structured review. Cancer Causes and Control, 16(1), 63–70.PubMedCrossRefGoogle Scholar
  53. 53.
    Phillips, K. A., Mayer, M. L., & Aday, L. A. (2000). Barriers to care among racial/ethnic groups under managed care. Health Affairs (Millwood), 19(4), 65–75.CrossRefGoogle Scholar
  54. 54.
    Baer, H., Allen, S., & Braun, L. (2000). Knowledge of human papillomavirus infection among young adult men and women: Implications for health education and research. Journal of Community Health, 25(1), 67–78.PubMedCrossRefGoogle Scholar
  55. 55.
    Ramirez, J. E., Ramos, D. M., Clayton, L., Kanowitz, S., & Moscicki, A. B. (1997). Genital human papillomavirus infections: Knowledge, perception of risk, and actual risk in a nonclinic population of young women. J Womens Health, 6(1), 113–121.PubMedCrossRefGoogle Scholar
  56. 56.
    Adams, E. K., Breen, N., & Joski, P. J. (2007). Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and pap test utilization among white, Hispanic, and African American women: 1996–2000. Cancer, 109(S2), 348–358.PubMedCrossRefGoogle Scholar
  57. 57.
    Ryerson, A. B., Benard, V. B., & Major, A. C. (2005). The National Breast and Cervical Cancer Early Detection Program: 1991–2002 National Report. Atlanta: The Centers for Disease Control and Prevention.Google Scholar
  58. 58.
    The Centers for Disease Control and Prevention. National Breast and Cervical Cancer Early Detection Program. Available at http://www.cdc.gov/cancer/nbccedp/. Accessed 29 March 2008.
  59. 59.
    Department of Health and Human Services. Medicaid Special Coverage Conditions. Breast and Cervical Cancer: Prevention and Treatment. Available at http://www.cms.hhs.gov/MedicaidSpecialCovCond/02_BreastandCervicalCancer_PreventionandTreatment.asp. Accessed 29 March 2008.
  60. 60.
    CDC. Racial and ethnic approaches to community health (REACH) 2010. The Centers for Disease Control and Prevention 2007. Available at http://www.cdc.gov/reach. Accessed 8 January 2008.
  61. 61.
    Freeman, H. P., & Vydelingum, N. A. (2006). The role of the special populations networks program in eliminating cancer health disparities. Cancer, 107(8 Suppl), 1933–1935.PubMedCrossRefGoogle Scholar
  62. 62.
    Jackson, F. E., Chu, K. C., & Garcia, R. (2006). Special Populations Networks—how this innovative community-based initiative affected minority and underserved research programs. Cancer, 107(8 Suppl), 1939–1944.PubMedCrossRefGoogle Scholar
  63. 63.
    CDC. (2007). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 56, 1–24.Google Scholar
  64. 64.
    Villa, L. L., Costa, R. L., Petta, C. A., et al. (2006). High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. British Journal of Cancer, 95(11), 1459–1466.PubMedCrossRefGoogle Scholar
  65. 65.
    The Future II Study Group. (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine, 356(19), 1915–1927.CrossRefGoogle Scholar
  66. 66.
    Haupt, R. M. Gardasil update: End-of-study and adult women. Paper presented at ACIP, Atlanta, GA, 27 Feb 2008.Google Scholar
  67. 67.
    Olsson, S. E., Villa, L. L., Costa, R. L., et al. (2007). Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine, 25(26), 4931–4939.PubMedCrossRefGoogle Scholar
  68. 68.
    Villa, L. L., Ault, K. A., Giuliano, A. R., et al. (2006). Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine, 24(27–28), 5571–5583.PubMedCrossRefGoogle Scholar
  69. 69.
    Giannini, S. L., Hanon, E., Moris, P., et al. (2006). Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine, 24(33–34), 5937–5949.PubMedCrossRefGoogle Scholar
  70. 70.
    Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmerón, J., Wheeler, C. M., et al., for the HPV PATRICIA study group. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet, 369(9580), 2161–2170.Google Scholar
  71. 71.
    Harper, D. M., Franco, E. L., Wheeler, C. M., et al. (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet, 367(9518), 1247–1255.PubMedCrossRefGoogle Scholar
  72. 72.
    Harper, D., Gall, S., Naud, P., et al. (2008). Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow up through 6.4 years in women vaccinated with cervarix TM (GSK’s HPV 16/18 AS04 Candidate Vaccine). Paper presented at SGO Conference, Tampa, FL, 2008.Google Scholar
  73. 73.
    Gall, S., Teixeira, J., Wheeler, C., Naud, P., Harper, D. M., Franco, E. L., et al., on behalf of the HPV Vaccine Study Group. Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP AS04 candidate vaccine. In Proceedings of the AACR Annual Meeting 2007. Available at http://www.aacr.org/home/scientists/meetings-workshops/annual-meeting-2007/publications.aspx. Accessed 18 April 2008.
  74. 74.
    Schwarz, T. F., & Dubin, G. (2007). Women HVSIfA. Human papillomavirus (HPV) 16/18 AS04 virus-like particle (VLP) cervical cancer vaccine is immunogenic and well tolerated 18 months after vaccination in women up to 55 years. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 2007, 25, (18S (June 20 Supplement)).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Department of Family Nursing CareThe University of Texas Health Science Center at San AntonioSan AntonioUSA

Personalised recommendations